RU2008146936A - APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY - Google Patents
APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY Download PDFInfo
- Publication number
- RU2008146936A RU2008146936A RU2008146936/15A RU2008146936A RU2008146936A RU 2008146936 A RU2008146936 A RU 2008146936A RU 2008146936/15 A RU2008146936/15 A RU 2008146936/15A RU 2008146936 A RU2008146936 A RU 2008146936A RU 2008146936 A RU2008146936 A RU 2008146936A
- Authority
- RU
- Russia
- Prior art keywords
- combination
- rimonabant
- pharmaceutical composition
- diuretic
- individually
- Prior art date
Links
Abstract
1. Применение римонабанта для получения лекарственного средства, пригодного при лечении и профилактике заболеваний, связанных с ожирением и/или дислипидемиями, выбранных из метаболического синдрома и стеатоза. ! 2. Применение по п.1 для профилактики и лечения метаболического синдрома. ! 3. Применение по п.1 для профилактики и лечения стеатоза. ! 4. Применение по п.1, в котором римонабант комбинируют с другим действующим началом, выбранным из одного из следующих терапевтических классов: ! антагонист рецепторов АТ1 ангиотензина II, индивидуально или в комбинации с диуретиком или с антагонистом кальция; ! ингибитор фермента превращения, индивидуально или в комбинации с диуретиком; ! антагонист кальция; ! бета-блокатор, индивидуально или в комбинации с диуретиком или антагонистом кальция; ! антигиперлипемическое или антигиперхолистеринемическое средство; ! антидиабетическое средство; ! другой агент против ожирения. ! 5. Применение по одному из пп.1-4, в котором римонабант используют в дозе от 5 до 50 мг. ! 6. Фармацевтическая композиция, содержащая в комбинации римонабант и антагонист рецепторов АТ1 ангиотензина II, индивидуально или в комбинации с диуретиком. ! 7. Фармацевтическая композиция по п.6, содержащая в комбинации римонабант и ирбесартан. ! 8. Фармацевтическая композиция по п.6, содержащая в комбинации римонабант, ирбесартан и гидрохлортиазид. ! 9. Фармацевтическая композиция, содержащая в комбинации римонабант и ингибитор фермента превращения, индивидуально или в комбинации с диуретиком. ! 10. Фармацевтическая композиция, содержащая в комбинации римонабант и антагонист кальция. ! 11. Фармацевтическая композиция, с� 1. The use of rimonabant to obtain a medicine suitable for the treatment and prevention of diseases associated with obesity and / or dyslipidemia, selected from metabolic syndrome and steatosis. ! 2. The use according to claim 1 for the prevention and treatment of metabolic syndrome. ! 3. The use according to claim 1 for the prevention and treatment of steatosis. ! 4. The use according to claim 1, in which rimonabant is combined with another active principle selected from one of the following therapeutic classes:! angiotensin II AT1 receptor antagonist, individually or in combination with a diuretic or calcium antagonist; ! a conversion enzyme inhibitor, individually or in combination with a diuretic; ! calcium antagonist; ! beta-blocker, individually or in combination with a diuretic or calcium antagonist; ! antihyperlipemic or antihypercholesterolemic agent; ! antidiabetic agent; ! another anti-obesity agent. ! 5. The use according to one of claims 1 to 4, in which rimonabant is used in a dose of 5 to 50 mg. ! 6. A pharmaceutical composition comprising, in combination, rimonabant and an angiotensin II AT1 receptor antagonist, individually or in combination with a diuretic. ! 7. The pharmaceutical composition according to claim 6, containing in combination rimonabant and irbesartan. ! 8. The pharmaceutical composition according to claim 6, containing in combination rimonabant, irbesartan and hydrochlorothiazide. ! 9. A pharmaceutical composition comprising, in combination, rimonabant and a conversion enzyme inhibitor, individually or in combination with a diuretic. ! 10. A pharmaceutical composition comprising rimonabant and a calcium antagonist in combination. ! 11. Pharmaceutical composition, s
Claims (14)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0312553 | 2003-10-24 | ||
FR0312553A FR2861300B1 (en) | 2003-10-24 | 2003-10-24 | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME |
FR0314763A FR2861301B1 (en) | 2003-10-24 | 2003-12-15 | USE OF THE PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME. |
FR0314763 | 2003-12-15 | ||
FR0401193 | 2004-02-05 | ||
FR0403252 | 2004-03-26 | ||
FR0403252A FR2861303A1 (en) | 2003-10-24 | 2004-03-26 | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006117790/15A Division RU2357731C2 (en) | 2003-10-24 | 2004-10-22 | Application of pirasole derivative for obtainment of medicine for prevention and treatment of dyslipidemia and diseases related to dyslipidemia and/or obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2008146936A true RU2008146936A (en) | 2010-06-10 |
Family
ID=42681086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008146936/15A RU2008146936A (en) | 2003-10-24 | 2008-11-27 | APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2008146936A (en) |
-
2008
- 2008-11-27 RU RU2008146936/15A patent/RU2008146936A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2678958C (en) | Heterocyclic aspartyl protease inhibitors | |
GEP20084527B (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
RU2006117790A (en) | APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY | |
EA200700049A1 (en) | PREPARATIVE FORMS OF ORAL MEDICINAL FORMS OF MEMANTINE WITH MODIFIED SURVIVAL | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
DE60315674D1 (en) | NEW IMIDAZOPYRIDINE AND ITS USE | |
AR064012A2 (en) | COMPOSITIONS AND COMBINATIONS OF ACTIVATOR (ES) OF THE PEROXISMAL PROLIFERATION ACTIVATION RECEIVER (PPAR) AND ESTEROL ABSORPTION INHIBITOR (ES) THE USE OF SUCH COMPOSITIONS FOR THE MANUFACTURE OF A MEDICINAL TREATMENT FOR OBJECTIVE OBJECTIVE REDUCTION OBJECTIVES | |
MX2008013836A (en) | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
SE504184C2 (en) | Use of certain 3-HT3 antagonists for the preparation of drugs | |
JO2355B1 (en) | CGRP receptor antagonists | |
MY148233A (en) | Heterocyclic aspartyl protease inhibitors | |
AU6161499A (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
EP1775283A4 (en) | 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor | |
NZ564696A (en) | Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
Schiffrin | Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature | |
DE602004011394D1 (en) | Thiazolderivate | |
JP2009518415A5 (en) | ||
MY154591A (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
NZ609533A (en) | Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats | |
MX2012001160A (en) | Sphingosine-1-phosphate receptor agonists. | |
EP1856100A4 (en) | Cgrp receptor antagonists | |
RU2007119067A (en) | MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA | |
ATE399164T1 (en) | ANTAGONISTS OF THE OPIOID RECEPTOR | |
SE0402635D0 (en) | Chemical compounds | |
AR038858A1 (en) | COMBINATION |